ImmunityBio Reports Median Overall Survival Not Yet Reached and Lymphopenia Reversed in Recurrent Glioblastoma Patients Receiving ANKTIVA® Plus CAR-NK, Chemo-Free Therapy
ImmunityBio, Inc. (IBRX)
Company Research
Source: Business Wire
Primary endpoint of QUILT-3.078 is overall survival; median overall survival has not yet been reached, with 19 of 23 enrolled patients alive as of January 22, 2026Fourteen patients have evaluable data, with the longest survival from time of disease recurrence reaching 12 months to date and ongoingBaseline mean absolute lymphocyte count (ALC) among these 14 patients was 0.9 x 103/uL, confirming severe lymphopenia at enrollmentALC increased within one treatment cycle, with mean ALC rising to = 1.4 x 103/uL (p Immune competence (as measured by ALC) was maintained, with statistically significant increases from baseline observed at all assessments through 20 weeks (p = 0.026) with ANKTIVA® + CAR-NKANKTIVA + CAR-NK demonstrated a manageable safety profile following a total of 219 doses administered to date, with three treatment-related serious adverse events reported among 41 GBM patients (2L and 3L+) enrolled across QUILT-3.078 (N=23) and single-patient INDs (N=18)Randomized controlled tri
Show less
Read more
Impact Snapshot
Event Time:
IBRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IBRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IBRX alerts
High impacting ImmunityBio, Inc. news events
Weekly update
A roundup of the hottest topics
IBRX
News
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ImmunityBio, Inc. - IBRXPR Newswire
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ImmunityBio, Inc. - IBRXGlobeNewswire
- ImmunityBio (NASDAQ:IBRX) had its price target raised by analysts at HC Wainwright from $8.00 to $10.00. They now have a "buy" rating on the stock.MarketBeat
- Stock Market Today, Jan. 23: ImmunityBio Falls After Gaining Over 200% in a Month [Yahoo! Finance]Yahoo! Finance
- ImmunityBio (NASDAQ:IBRX) had its "buy" rating reaffirmed by analysts at BTIG Research.MarketBeat
IBRX
Earnings
- 5/12/25 - Miss
IBRX
Sec Filings
- 1/26/26 - Form 8-K
- 1/21/26 - Form 4
- 1/21/26 - Form 4
- IBRX's page on the SEC website